Since 20 could not completely be separated from unidentified side products, it was converted into the corresponding nonaflate 52. Compound 20 (68 mg, 0.18 mmol) was dissolved in dry THF (0.11 mL) and treated with NaH (15 mg, 0.37 mmol). NfF (67 μL, 0.37 mmol) was added and stirred for 10 h. After complete conversion of the starting S5 material (as indicated by TLC), the reaction was quenched by the addition of MeOH.
The aqueous layer was extracted with Et 2 O, dried with Na 2 SO 4 , filtered and the solvent removed under reduced pressure. The crude product was purified by flash column chromatography on silica gel (eluent: hexane/ethyl acetate 100:0 to 70:30, linear gradient) to afford 61 mg (56%) of 52 as a colorless oil. 
S6 (S)-2-tert-Butyl-6-[(tert-butyldimethylsiloxy)phenylmethyl]-3-methoxypyridin-

4(1H)-one (22)
According to procedure 1, methoxyallene (0.25 mL, 3.08 mmol), n-BuLi (2.5 M in hexanes, 1.16 mL, 2.90 mmol), pivalonitrile (83 mg, 1.00 mmol) and TBS-mandelic acid 21 (1.60 g, 6.00 mmol) were converted into the β-ketoenamide, which was then treated with 18.2, 25.8 (3 q, s, OTBS), 28.5, 35.3 (q, s, 58.8 (q, OMe), 73.4 (d, 113.9 (d, 126.4, 128.7, 128.9, 140.9 (3 d, s, Ph), 145.6, 146.7, 147 .1 (3 s, C-2, C-3, C-6), 175. 
S11 (S,S)-2,6-Di-sec-butyl-3-methoxypyridin-4(1H)-one (32)
According to procedure 1, methoxyallene (0.38 mL, 4.7 mmol), n-BuLi (2.5 M in hexanes, 1.65 mL, 4.13 mmol), (S)-2-methylbutyronitrile (31) (162 μL, 1.53 mmol) and (S)-2-methylbutyric acid (17) (1.0 mL, 9.18 mmol) were converted into the β-ketoenamide, which was then treated with NEt 3 (1.91 mL, 13.8 mmol) and TMSOTf was slowly allowed to reach r.t. The reaction was quenched by the addition of aq. sat.
NaHCO 3 (15 mL), the phases were separated and the aqueous layer was extracted with Et 2 O (3x20 mL). The combined organic layers were dried with Na 2 SO 4 , filtered and the solvent was removed under reduced pressure. The crude product was purified by flash column chromatography (silica gel, hexane/EtOAc = 9:1 to 8:2) to provide 482 mg (58%) of the β-methoxy-β-ketoenamide. Following the typical procedure, the β-methoxy-β-ketoenamide (70 mg, 0.12 mmol) was cyclized with TMSOTf (0.07 mL, 0.36 mmol)
and NEt 3 (0.06 mL, 0.36 mmol) in 1,2-dichloroethane (2.5 mL) at 70 °C for 1 d. 
6-{(R)-[tert-Butyldimethylsiloxy)(phenyl]methyl}-2-{(S)-[tert-butyldimethylsilyloxy]-(phenyl)methyl}-3-methoxypyridin-4(1H)-one (34)
[α] D 2 22 = +41.6 (c = 0.6, CHCl 3 ). According to procedure 1, methoxyallene (0.25 mL, 3.1 mmol), n-BuLi (2.5 M in hexanes, 1.16 mL, 2.90 mmol), TBS-mandelonitrile 36 (247 mg, 1.00 mmol) and trifluoroacetic acid (1.54 mL, 6.00 mmol) were converted to the β-ketoenamide, which was then treated with NEt 3 (0.42 mL, 3.00 mmol) and TMSOTf (0.58 mL, 3.00 mmol).
The crude material was purified by flash column chromatography on silica gel (eluent:
hexane/ethyl acetate 100:0 to 50:50 linear gradient) to afford 37 as a colorless oil (152 mg, 37%). In CDCl 3 37 was found to be in equilibrium with the corresponding pyridone.
At r.t. the ratio pyridinol/pyridone was ≈ 4:6. Pyridinol. 
(S)-2-(2-Phenylpropyl)-6-(trifluoromethyl)pyridin-4-ol (39)
Following procedure 1, methoxyallene (0.19 mL, 2.3 mmol) was treated with n-BuLi (2. 
(S)-2-sec-Butyl-3-methoxy-6-(trifluoromethyl)pyridin-4(1H)-one (40)
According to procedure 1, methoxyallene (0.75 mL, 9.3 mmol), n-BuLi (2.5 M in hexanes, 3.24 mL, 8.10 mmol), (S)-2-methylbutyronitrile (31) (0.32 mL, 3.00 mmol) and trifluoroacetic acid (1.34 mL, 18.0 mmol) were converted into the β-ketoenamide which was then treated with NEt 3 (1.25 mL, 9.00 mmol) and TMSOTf (1.74 mL, 9.00 mmol). 34-7.29, 7.36-7.39, 7.40-7.46, 7.53-7.64, 7.87-7 .91 (5 m, 10 H, Ph) ppm. H 7.64, N 3.22, found: C 72.12, H 7.36, N 3.19 . 128.1, 128.5, 128.7, 129.4, 129.5 (6 d, Ph), 140.8, 142.5, 143.2, 148.4, 156.9, 161 .7 (6 s, Ph, C-2, C-3, C-4, C-6) ppm. IR (neat):  = 3020 (C-H), 2400-1550 (C=C) cm 
